

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO (First Supplemental) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/528,029 (U.S. Nat'l Phase of PCT/AU2003/001209)
				Filing Date	§ 371 Date: December 16, 2005
				First Named Inventor	Stephenson
				Art Unit	1642
				Examiner Name	Mark Halvorson
Sheet	1	of	1	Attorney Docket Number	2381.0010000/MAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/MH/	NPL1	BODEY, B. "Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells," <i>Expert. Opin. Biol. Ther.</i> 1:603-617 Ashley Publications Ltd (2001)	
/MH/	NPL2	CRAGG, M.S. <i>et al.</i> , "Signaling antibodies in cancer therapy," <i>Cur. Opin. Immunol.</i> 11:541-547 Elsevier Science Ltd. (1999)	
/MH/	NPL3	HUDSON, P.J., "Recombinant antibody constructs in cancer therapy," <i>Cur. Opin. Immunol.</i> 11:548-557 Elsevier Science Ltd. (1999)	

844678v1

Examiner Signature	/Mark Halvorson/	Date Considered	08/29/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.